Skip to main content

How is Bendeka different to Treanda?

Medically reviewed by Carmen Pope, BPharm. Last updated on June 6, 2024.

Official answer

by drugclasses.com

Although Bendeka and Treanda both contain bendamustine hydrochloride, there are two main differences between them.

The first difference is that it takes less time to administer the same dosage of Bendeka compared to Treanda.

  • An infusion of Bendeka can be administered over 10 minutes whereas an infusion of Treanda must be administered over 60 minutes.

The second difference is that Bendeka is compatible with polycarbonate or acrylonitrile-butadiene-styrene (ABS)-containing infusion equipment, and Treanda injection is not.

  • Treanda Injection cannot be used with closed system transfer devices (CSTDs), adapters, and syringes containing polycarbonate or acrylonitrile-butadiene-styrene (ABS) as significant absorption of the active ingredient bendamustine to surfaces containing these ingredients will occur.
  • This is because Treanda injection contains N, N-dimethylacetamide (DMA), which binds to polycarbonate or acrylonitrile-butadiene-styrene (ABS).
  • In addition, only polypropylene syringes with a metal needle and polypropylene hub can be used to withdraw and transfer Treanda Injection into the infusion bag. Polypropylene syringes are translucent in appearance.

Another difference concerns the confusion that exists by having two types of Treanda formulations available: Treanda Injection and Treanda for Injection which is a powder that requires mixing with sterile water before diluting.

The concentration of bendamustine hydrochloride also differs in these preparations.

  • In Treanda injection the concentration of bendamustine is 90 mg/mL.
  • After reconstituting the concentration of bendamustine in Treanda for injection is 5 mg/mL.

Treanda injection and Treanda for injection should not be mixed or combined.

In 2016, Teva replaced Treanda with Bendeka, although Treanda is still available through Cephalon, a subsidiary company of Teva.

Related questions

Bendeka Vs Treanda: Similarities

There are many similarities between Bendeka and Treanda:

  • Both Bendeka and Treanda contain bendamustine HCl
  • Bendeka has the same indications for use as Treanda and may be used to treat chronic lymphocytic leukemia (CLL) or indolent (slow-growing) B-cell non-Hodgkin lymphoma that has progressed despite treatment.
  • Bendeka and Treanda have the same side effects.
References

Read next

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

Does Truxima make you gain weight?

Weight gain has been reported in 11% of patients being treated with Truxima (rituximab) for non-Hodgkin’s lymphoma (NHL). Be sure to contact your doctor right away if you have a rapid or unexplained weight gain or fluid retention (edema), nausea, vomiting, diarrhea, or lack of energy when using Truxima, as you may need immediate medical care. Continue reading

Is Venclexta (venetoclax) chemotherapy?

Venclexta (venetoclax) is a targeted treatment rather than a type of chemotherapy. Chemotherapy is defined as a drug treatment that kills fast-growing cells in your body. Venclexta works by binding to a specific protein called BCL-2 which is overexpressed on cancerous cells in people with cancers such as AML and CLL. By binding to this protein Venclexta kills cancerous CLL and AML lymphocytes, in preference to other fast-growing cells. Continue reading

Related medical questions

Drug information

Related support groups